|
|
|
| Effect of recombinant interferon α-2b inhalation combined with chest wall vibration in the treatment of children with bronchiolitis and its effect on immune function |
| YU Xiao ZHOU Yan LI Dan ZHU Zhankui▲ |
| The First Department of Pediatrics, Fuyang Women’s and Children’s Hospital, Anhui Province, Fuyang 236504, China |
|
|
|
Abstract Objective To investigate the effect of recombinant interferon α-2b inhalation combined with chest wall vibration in the treatment of children with bronchiolitis and its effect on immune function. Methods A total of 120 children with bronchiolitis admitted to Fuyang Women’s and Children’s Hospital from March 2018 to May 2021 were selected as the research subjects. They were divided into combination group, observation group, and control group, with 40 cases in each group. The children in combination group received recombinant interferon α-2b inhalation combined with chest wall vibration therapy, observation group received recombinant interferon α-2b inhalation therapy, and control group received chest wall vibration therapy. The treatment lasted for seven days. The clinical efficacy of each group was compared; the expressions of interleukin-6 (IL-6), immunoglobulin G (IgG), IgA, IgE, and eosinophil (EOS) were compared before and after treatment; the recurrence rate of each group was compared after six months of follow-up. Results The clinical efficacy of combination group was better than that of observation group and control group (P＜0.05). After treatment, IL-6, IgE, and EOS were lower than those before treatment; IgG was higher than that before treatment (P＜0.05). After treatment, IL-6, IgE, and EOS in combination group were lower than those in observation group and control group; IgG was higher than that in observation group and control group (P＜0.05). The recurrence rate of combination group was lower than that of observation group and control group (P＜0.05). Conclusion Recombinant interferon α-2b inhalation combined with chest wall vibration therapy has good utility value for children with bronchiolitis, it can effectively reduce the clinical symptoms of children, and regulate the immune function, and has a better application value.
|
|
|
|
|
|
[1] 温潇慧，徐慧，唐晓蕾，等.儿童肺炎支原体细支气管炎临床特点及预后研究[J].中国实用儿科杂志，2020，35（12）：963-967.
[2] 李宏颖，齐玥莹.重症肺炎患儿血清及诱导痰液细胞因子动态变化与预后相关性的研究[J].中国医药科学，2021， 11（21）：178-181.
[3] 唐艳姣，黄寒，钟礼立.儿童闭塞性细支气管炎研究进展[J].临床儿科杂志，2018，36（7）：563-568.
[4] 贺海珊，邱雪雁，刘阿玲，等.我院中重度毛细支气管炎患儿主要治疗药物的使用情况调查及合理性评价[J].中国药房，2018，29（14）：1988-1991.
[5] 苏若伊，彭东红.2016年重庆医科大学附属儿童医院副流感病毒感染流行病学特点及临床特征[J].重庆医科大学学报，2018，43（7）：957-960.
[6] Kavaliunaite E，Aurora P. Diagnosing and managing bronchiolitis obliterans in children[J]. Expert Rev Respir Med，2019，13（5）：481-488.
[7] 徐烔烔，吴安娜，倪舒芹.重组人干扰素治疗儿童呼吸道合胞病毒感染的临床疗效[J].中华医院感染学杂志，2019， 29（18）：2861-2864，2868.
[8] Zielińska A，Jassem-Bobowicz JM，Kwiatkowska J. Oxygen therapy with high-flow nasal cannulas in children with acute bronchiolitis [J]. Anaesthesiol Intensive Ther，2019，51（1）：51-55.
[9] 史瑞明，刁敏，李成尧.毛细支气管炎治疗新观点[J].中国实用儿科杂志，2019，34（9）：749-752.
[10] 刁敏，张冲林，赵秀侠.重组人干扰素α-2b联合布地奈德、异丙托溴铵雾化对小儿毛细支气管炎疗效及IL-18、IL-33的影响[J].中国细胞生物学学报，2020，42（3）：485- 490.
[11] Ralston SL，Lieberthal AS，Meissner HC，et al. Clinical practice guideline：the diagnosis，management，and prevention of bronchiolitis [J]. Pediatrics，2014，134（5）：e1474- e1502.
[12] 江载芳，申昆玲，沈颖，等.诸福棠实用儿科学[M].8版.北京：人民卫生出版社，2014.
[13] Gomes GR，Donadio MVF. Effects of the use of respiratory physiotherapy in children admitted with acute viral bronchiolitis [J]. Arch Pediatr，2018，25（6）：394-398.
[14] 周瑛瑛，宋卫娜，马俊霞.呼吸道菌群种类和数量与小儿毛细支气管炎的关系[J].中国微生态学杂志，2021， 33（1）：71-74.
[15] Joseph MM，Edwards A. Acute bronchiolitis：assessment and management in the emergency department [J]. Pediatr Emerg Med Pract，2019，16（10）：1-24.
[16] 蒋俊，郭琼英，刘挺，等.婴幼儿毛细支气管炎中医证型分布规律及中医分型论治的应用研究[J].中华中医药学刊，2018，36（5）：1169-1172.
[17] 王天玥，尚云晓，樊映红，等.雾化吸入布地奈德治疗毛细支气管炎的临床多中心研究[J].中国实用儿科杂志，2020，35（3）：213-216，221.
[18] 金英姬，张亚明.对雾化吸入激素治疗毛细支气管炎的看法[J].中华医学杂志，2018，98（8）：591.
[19] 严永东，戴鸽.儿童腺病毒肺炎并闭塞性细支气管炎的诊治进展[J].中华实用儿科临床杂志，2020，35（22）：1685- 1689.
[20] 杨男，尚云晓.毛细支气管炎与哮喘的关系[J].中国实用儿科杂志，2019，34（9）：737-742.
[21] 申昆玲，尚云晓，张国成，等.α干扰素在儿科临床合理应用专家共识[J].中华实用儿科临床杂志，2018，33（17）：1301-1308.
[22] Sastre B，García-García ML，Ca?觡as JA，et al. Bronchiolitis and recurrent wheezing are distinguished by type 2 innate lymphoid cells and immune response [J]. Pediatr Allergy Immunol，2021，32（1）：51-59.
[23] 李德优，许景怀，刘明凤.重组干扰素α2b雾化吸入在小儿毛细支气管炎治疗中的临床疗效观察[J].中国当代医药，2020，27（22）：121-123.
[24] 崔利丹，金志鹏，王琪，等.重组人干扰素α-1b联合人免疫球蛋白对毛细支气管炎重症患儿临床疗效及血清细胞因子表达的影响[J].中国医院药学杂志，2018，38（4）：403-406.
[25] 毛庆东.重组人干扰素α2b氧驱雾化吸入佐治毛细支气管炎疗效及安全性观察[J].中国临床药理学与治疗学，2018，23（8）：927-931.
[26] 蒋梅卿.综合护理干预应用在儿童肺炎护理中的效果[J].中国医药科学，2021，11（8）：124-127. |
|
|
|
